Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice
机构：[1]Kunming Med Univ, Yunnan Clin Res Ctr Digest Dis, Yunnan Inst Digest Dis, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China昆明医科大学附属第一医院消化内科内科科室[2]Yunnan Univ, Sch Life Sci, State Key Lab Conservat & Utilizat Bioresources Y, Kunming, Yunnan, Peoples R China[3]Kunming Med Univ, Fac Basic Med, Kunming, Yunnan, Peoples R China
Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown. MicroRNAs (miRNAs) are key mediators in regulating endoplasmic reticulum (ER) stress during NAFLD, and the deregulation of miRNAs has been demonstrated in NAFLD pathophysiology. The present study aimed to identify whether fenofibrate could influence miRNA expression in NAFLD and investigate the specific mechanism of action of fenofibrate in lipid metabolism disorder-associated diseases. We found that fenofibrate alleviated ER stress and increased the levels of SERCA2b, which serves as a regulator of ER stress. Additionally, the levels of let-7 miRNA were regulated by fenofibrate; let-7 was found to target the 3 ' untranslated region of SERCA2b. The present data suggest that the protective effects of fenofibrate against insulin resistance and its suppressive activity against excessive hepatic lipid accumulation may be related to the alteration of the let-7/SERCA2b axis and alleviation of ER stress.
基金：
the National Natural
Science Foundation of China (No. 81560099 and No. 81760108); a
key project from the Department of Science and Technology of
Yunnan Province (2018FA039); the Applied Basic Research Projects
of Yunnan Province (202001AY070001-013); Scientific Research
Fund Project of Yunnan Education Department (2019Y0353).
第一作者机构：[1]Kunming Med Univ, Yunnan Clin Res Ctr Digest Dis, Yunnan Inst Digest Dis, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Dan,Niu Shanzhuang,Ma Yicheng,et al.Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice[J].FRONTIERS IN PHARMACOLOGY.2022,12:doi:10.3389/fphar.2021.770652.
APA：
Zhang, Dan,Niu, Shanzhuang,Ma, Yicheng,Chen, Hang,Wen, Yu...&Ma, Lanqing.(2022).Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice.FRONTIERS IN PHARMACOLOGY,12,
MLA：
Zhang, Dan,et al."Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice".FRONTIERS IN PHARMACOLOGY 12.(2022)
